Abstract
A prominent feature of brain pathology in Alzheimer's disease is a robust activation of the neuronal lysosomal system and major cellular pathways converging on the lysosome, namely, endocytosis and autophagy. Recent studies that identify a disturbance of the endocytic pathway as one of the earliest known manifestation of Alzheimer's disease provide insight into how β-amyloidogenesis might be promoted in sporadic Alzheimer's disease, the most prevalent and least well understood form of the disease. Primary lysosomal dysfunction has historically been linked to neurodegeneration. New data now directly implicate cathepsins as proteases capable of initiating, as well as executing, cell death programs in certain pathologic states. These and other studies support the view that the progressive alterations of lysosomal function observed during aging and Alzheimer's disease contribute importantly to the neurodegenerative process in Alzheimer's disease.
Similar content being viewed by others
REFERENCES
Roberts, P. J. 1979. Biochemistry of dementia: based on a Workshop on Biochemistry of the Dementias, held at University of Southampton. Chichester; New York: Wiley, c1980, New York.
Goedert, M. 1993. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 16:460-465.
Beyreuther, K., Pollwein, P., Multhaup, G., Monning, U., Konig, G., Dyrks, T., Schubert, W., and Masters, C. L. 1993. Regulation and expression of the Alzheimer's beta/A4 amyloid protein precursor in health, disease, and Down's syndrome. Ann. NY Acad. Sci. 695:91-102.
Selkoe, D. J. 1994. Normal and abnormal biology of the betaamyloid precursor protein. Annu. Rev. Neurosci. 17:489-517.
Braak, H. and Braak, E. 1992. The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci. Res. 15:6-31.
Heston, L. L., Mastri, A. R., Anderson, V. E., and White, J. 1981. Dementia of the Alzheimer type. Clinical genetics, natural history, and associated conditions. Arch. Gen. Psychiatry 38:1085-1090.
Mullan, M. and Crawford, F. 1993. Genetic and molecular advances in Alzheimer's disease. Trends Neurosci. 16:398-403.
Mattson, M. P., Barger, S. W., Cheng, B., Lieberburg, I., Smith-Swintosky, V. L., and Rydel, R. E. 1993. beta-Amyloid precursor protein metabolites and loss of neuronal Ca2+homeostasis in Alzheimer's disease. Trends Neurosci. 16:409-414.
Selkoe, D. J. 1993. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. 16:403-409.
Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C. M., Kim, G., Seekins, S., Yager, D., Slunt, H. H., Wang, R., Seeger, M., Levey, A. I., Gandy, S. E., Copeland, N. G., Jenkins, N. A., Price, D. L., Younkin, S. G., and Sisodia, S. S. 1996. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 17:1005-1013.
Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., and Selkoe, D. J. 1997. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice [see comments]. Nat. Med. 3:67-72.
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C. M., Pereztur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., Morgan, D., Gordon, M. N., Holcomb, L., Refolo, L., Zenk, B., Hardy, J., and Younkin, S. 1996. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383: 710-713.
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., and Younkin, S. 1996. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease [see comments]. Nat. Med. 2:864-870.
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., and Tsuda, T. 1995. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376:775-778.
Wolozin, B., Iwasaki, K., Vito, P., Ganjei, J. K., Lacana, E., Sunderland, T., Zhao, B., Kusiak, J. W., Wasco, W., and D'Adamio, L. 1996. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 274:1710-1713.
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., and Pericak-Vance, M. A. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families [see comments]. Science 261:921-923.
Riezman, H., Woodman, P. G., van Meer, G., and Marsh, M. 1997. Molecular mechanisms of endocytosis. Cell 91:731-738.
Gabel, C. A., Goldberg, D. E., and Kornfeld, S. 1983. Identification and characterization of cells deficient in the mannose 6-phosphate receptor: evidence for an alternate pathway for lysosomal enzyme targeting. Proc. Natl. Acad. Sci. USA 80:775-779.
Stein, M., Zijderhand-Bleekemolen, J. E., Geuze, H., Hasilik, A., and von Figura, K. 1987. Mr 46,000 mannose 6-phosphate specific receptor: its role in targeting of lysosomal enzymes. Embo. J. 6:2677-2681.
Clague, M. J. 1998. Molecular aspects of the endocytic pathway [In Process Citation]. Biochem. J. 336:271-282.
Mahley, R. W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240:622-630.
Gutman, C. R., Strittmatter, W. J., Weisgraber, K. H., and Matthew, W. D. 1997. Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor. J. Neurosci. 17:6114-6121.
Laskowitz, D. T., Horsburgh, K., and Roses, A. D. 1998. Apolipoprotein E and the CNS response to injury. J. Cereb. Blood Flow Metab. 18:465-41.
Permanne, B., Perez, C., Soto, C., Frangione, B., and Wisniewski, T. 1997. Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants. Biochem. Biophys. Res. Commun. 240:715-720.
Webster, S. and Rogers, J. 1996. Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. J. Neurosci. Res. 46:58-66.
Wood, S. J., Chan, W., and Wetzel, R. 1996. Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 35:12623-12628.
Jordan, J., Galindo, M. F., Miller, R. J., Reardon, C. A., Getz, G. S., and LaDu, M. J. 1998. Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J. Neurosci. 18:195-204.
Miyata, M. and Smith, J. D. 1996. Apolipoprotein E allelespecific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Genet. 14:55-61.
Casadei, V. M. 1999. APOE-491 promoter polymorphism is a risk factor for late-onset Alzheimer's disease. Neurology 53:1888-1889.
Papassotiropoulos, A., Bagli, M., Kurz, A., Kornhuber, J., Forstl, H., Maier, W., Pauls, J., Lautenschlager, N., and Heun, R. 2000. A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease. Ann. Neurol. 47:399-403.
Kamboh, M. I., Ferrell, R. E., and DeKosky, S. T. 1998. Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene. Neurosci. Lett. 244:65-68.
King, N. D. and O'Brian., M. R. 1997. Identificatin of the Irp gene in Bradyrhizobium japonicum and its role in regulation of delta-aminolevulinic acid uptake. J. Bacteriol. 179:1828-31.
Tanzi, R. E., Kovacs, D. M., Kim, T. W., Moir, R. D., Guenette, S. Y., and Wasco, W. 1996. The gene defects responsible for familial Alzheimer's disease. Neurobiol. Dis. 3:159-168.
Wavrant-DeVrieze, F., Perez-Tur, J., Lambert, J. C., Frigard, B., Pasquier, F., Delacourte, A., Amouyel, P., Hardy, J., and Chartier-Harlin, M. C. 1997. Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. Neurosci. Lett. 227:68-70.
Papassotiropoulos, A., Bagli, M., Feder, O., Jessen, F., Maier, W., Rao, M. L., Ludwig, M., Schwab, S. G., and Heun, R. 1999. Genetic polymorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer's disease. Neurosci. Lett. 262:171-174.
Yamanaka, H., Kamimura, K., Tanahashi, H., Takahashi, K., Asada, T., and Tabira, T. 1998. Genetic risk factors in Japanese Alzheimer's disease patients: alpha1-ACT, VLDLR, and ApoE. Neurobiol. Aging. 19:S43-46.
Hu, Q., Kukull, W. A., Bressler, S. L., Gray, M. D., Cam, J. A., Larson, E. B., Martin, G. M., and Deeb, S. S. 1998. The human FE65 gene:genomic structure and an intronic biallelic polymorphism associated with sporadic dementia of the Alzheimer type. Human Genetics 103:295-303.
Blacker, D., Wilcox, M. A., Laird, N. M., Rodes, L., Horvath, S. M., Go, R. C., Perry, R., Watson, B., Jr., Bassett, S. S., McInnis, M. G., Albert, M. S., Hyman, B. T., and Tanzi, R. E. 1998. Alpha-2 macroglobulin is genetically associated with Alzheimer disease [see comments]. Nat. Genet. 19:357-360.
Liao, A., Nitsch, R. M., Greenberg, S. M., Finckh, U., Blacker, D., Albert, M., Rebeck, G. W., Gomez-Isla, T., Clatworthy, A., Binetti, G., Hock, C., Mueller-Thomsen, T., Mann, U., Zuchowski, K., Beisiegel, U., Staehelin, H., Growdon, J. H., Tanzi, R. E., and Hyman, B. T. 1998. Genetic association of an alpha2-macroglobulin (Val10001le) polymorphism and Alzheimer's disease. Hum. Mol. Genet. 7:1953-1956.
Montoya, S. E., Aston, C. E., DeKosky, S. T., Kamboh, M. I., Lazo, J. S., and Ferrel, R. E. 1998. Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease. Nat. Genet. 18:211-212.
Farrer, L. A., Abraham, C. R., Haines, J. L., Rogaeva, E. A., Song, Y., McGraw, W. T., Brindle, N., Premkumar, S., Scott, W. K., Yamaoka, L. H., Saunders, A. M., Roses, A. D., Auerbach, S. A., Sorbi, S., Duara, R., Pericak-Vance, M. A., and St. George-Hyslop, P. H. 1998. Association between bleomycin hydrolase and Alzheimer's disease in caucasians. Ann. Neurol. 44:808-811.
Grimaldi, L. M., Casadei, V. M., Ferri, C., Veglia, F., Licastro, F., Annoni, G., Biunno, I., De Bellis, G., Sorbi, S., Mariani, C., Canal, N., Griffin, W. S., and Franceschi, M. 2000. Association of early-onset Alzheimer's disease with an interleukin-1 alpha gene polymorphism [see comments]. Ann. Neurol. 47:361-365.
Nicoll, J. A., Mrak, R. E., Graham, D. I., Stewart, J., Wilcock, G., MacGowan, S., Esiri, M. M., Murray, L. S., Dewar, D., Love, S., Moss, T., and Griffin, W. S. 2000. Association of interleukin-1 gene polymorphisms with Alzheimer's disease [see comments]. Ann. Neurol. 47:365-368.
Hyman, B. T., Gomez-Isla, T., Briggs, M., Chung, H., and Nichols, S. 1996. Apolipoprotein E and cognitive change in an elderly population. Ann. Neurol. 40:55-66.
Roses, A. D. 1995. On the metabolism of apolipoprotein E and the Alzheimer diseases. Exp. Neurol. 132:149-156.
Roses, A. D. 1995. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann. Neurol. 38:6-14.
Sekijima, Y., Ikeda, S., Tokuda, T., Satoh, S., Hidaka, H., Hidaka, E., Ishikawa, M., and Yanagisawa, N. 1998. Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome. Eur. Neurol. 39:234-237.
Sabo, S. L., Lanier, L. M., Ikin, A. F., Khorkova, O., Sahasrabudhe, S., Greengard, P., and Buxbaum, J. D. 1999. Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein. J. Biol. Chem. 274:7952-7957.
Chyung, A. S. C., Greenberg, B. D., Cook, D. G., Doms, R. W., and Lee, V. M. 1997. Novel beta-secretase cleavage of beta-amyloid precursor protein in the endoplasmic reticulum/intermediate compartment of NT2N cells. J. Cell Biol. 138:671-680.
Cook, D. G., Forman, M. S., Sung, J. C., Leight, S., Kolson, D. L., Iwatsubo, T., Lee, V. M., and Doms, R. W. 1997. Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat. Med. 3:1021-1023.
Hartmann, H., Busciglio, J., Baumann, K. H., Staufenbiel, M., and Yankner, B. A. 1997. Developmental regulation of presenilin-1 processing in the brain suggests a role in neuronal differentiation. J. Biol. Chem. 272:14505-14508.
Xia, W., Zhang, J., Ostaszewski, B. L., Kimberly, W. T., Seubert, P., Koo, E. H., Shen, J., and Selkoe, D. J. 1998. Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid betaprotein in endoplasmic reticulum and Golgi. Biochemistry 37:16465-16471.
Peraus, G. C., Masters, C. L., and Beyreuther, K. 1997. Late compartments of amyloid precursor protein transport in SY5Y cells are involved in beta-amyloid secretion. J. Neurosci. 17:7714-7724.
Thinakaran, G., Borchelt, D. R., Lee, M. K., Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., Hardy, J., Levey, A. I., Gandy, S. E., Jenkins, N. A., Copeland, N. G., Price, D. L., and Sisodia, S. S. 1996. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17:181-190.
Tomita, S., Kirino, Y., and Suzuki, T. 1998. Cleavage of Alzheimer's amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway. Identification of intracellular compartments in which APP cleavage occurs without using toxic agents that interfere with protein metabolism. J. Biol. Chem. 273:6277-6284.
Xu, H., Sweeney, D., Wang, R., Thinakaran, G., Lo, A. C., Sisodia, S. S., Greengard, P., and Gandy, S. 1997. Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc. Natl. Acad. Sci. USA 94:3748-3752.
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., and Teplow, D. B. 1992. Amyloid beta-peptide is produced by cultured cells during normal metabolism [see comments]. Nature 359:322-325.
Koo, E. H. and Squazzo, S. L. 1994. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269:17386-17389.
Soriano, S., Chen, X., Chyung, A. S. C., Lee, V. M.-Y., and Koo, B. 1998. Role of the Secretory and Endocytic Pathways in the Production of Amyloid beta-peptides alpha-beta 1-40 and alpha-beta 1-42 in 6th International conference on Alzheimer's Disease, Amsterdam.
Stokin, G. B., Chyung, A. S. C., Perez, R. G., Lee, V. M.-Y., and Koo, E. 1998. The pathway of alpha-beta 42 production in APP with codon 717 mutation in 6th International Conference on Alzheimer's Disease, Amsterdam.
Perez, R. G., Soriano, S., Hayes, J. D., Ostaszewski, B., Xia, W., Selkoe, D. J., Chen, X., Stokin, G. B., and Koo, E. H. 1999. Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J. Biol. Chem. 274:18851-18856.
Cataldo, A. M., Barnett, J. L., Pieroni, C., and Nixon, R. A. 1997. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J. Neurosci. 17:6142-6151.
Cataldo, A., Peterhoff, C., Troncoso, J., T, G.-I., Hyman, B., and Nixon, R. 2000. Endocytic pathway abnormalities precede beta-amyloid deposition in sporadic Alzheimer's disease: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157:277-286.
Lai, F., Kammann, E., Rebeck, G. W., Anderson, A., Chen, Y., and Nixon, R. A. 1999. APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology 53:331-336.
Gorvel, J. P., Chavrier, P., Zerial, M., and Gruenberg, J. 1991. rab5 controls early endosome fusion in vitro. Cell 64:915-925.
Bucci, C., Parton, R. G., Mather, I. H., Stunnenberg, H., Simons, K., Hoflack, B., and Zerial, M. 1992. The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. Cell 70:715-728.
de Hoop, M. J., Huber, L. A., Stenmark, H., Williamson, E., Zerial, M., Parton, R. G., and Dotti, C. G. 1994. The involvement of the small GTP-binding protein Rab5a in neuronal endocytosis. Neuron 13:11-22.
Roses, A. D. 1996. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47:387-400.
Chavrier, P., Parton, R. G., Hauri, H. P., Simons, K., and Zerial, M. 1990. Localization of low molecular weight GTP binding proteins to exocytic and endocytic compartments. Cell 62:317-329.
van der Sluijs, P., Hull, M., Webster, P., Male, P., Goud, B., and Mellman, I. 1992. The small GTP-binding protein rab4 controls an early sorting event on the endocytic pathway. Cell 70:729-740.
Daro, E., van der Sluijs, P., Galli, T., and Mellman, I. 1996. Rab4 and cellubrevin define different early endosome populations on the pathway of transferrin receptor recycling. Proc. Natl. Acad. Sci. USA 93:9559-9564.
Stenmark, H., Vitale, G., Ullrich, O., and Zerial, M. 1995. Rabaptin-5 is a direct effector of the small GTPase Rab5 in endocytic membrane fusion. Cell 83:423-432.
Simonsen, A., Lippe, R., Christoforidis, S., Gaullier, J. M., Brech, A., Callaghan, J., Toh, B. H., Murphy, C., Zerial, M., and Stenmark, H. 1998. EEA1 links PI(3)K function to Rab5 regulation of endosome fusion [see comments]. Nature 394:494-498.
Cataldo, A. M., Barnett, J., and Nixon, R. A. 1998. Influences of Aging, APOE E genotype and presenilin mutations on endocytic abnormalities in Alzheimer's disease. [abstract] Society for Neuroscience 24:721.
van Broeckhoven, C. 1995. Presenilins and Alzheimer disease. Nat. Genet. 11:230-232.
Houlden, H., Crook, R., Backhovens, H., Prihar, G., Baker, M., Hutton, M., Rossor, M., Martin, J. J., Van Broeckhoven, C., and Hardy, J. 1998. ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families. Am. J. Med. Genet. 81:117-121.
Mattson, M. P. and Guo, Q. 1997. Cell and molecular neurobiology of presenilins: a role for the endoplasmic reticulum in the pathogenesis of Alzheimer's disease? J. Neurosci. Res. 50: 505-513.
Stein, M., Braulke, T., Krentler, C., Hasilik, A., and von Figura, K. 1987. 46-kDa mannose 6-phosphate-specific receptor: biosynthesis, processing, subcellular location and topology. Biol. Chem. 368:937-947.
Chevallier, N., Vizzavona, J., Marambaud, P., Baur, C. P., Spillantini, M., Fulcrand, P., Martinez, J., Goedert, M., Vincent, J. P., and Checler, F. 1997. Cathepsin D displays in vitro beta-secretase-like specificity. Brain Res. 750:11-19.
Dreyer, R. N., Bausch, K. M., Fracasso, P., Hammond, L. J., Wunderlich, D., Wirak, D. O., Davis, G., Brini, C. M., Buckholz, T. M., and Konig, G. 1994. Processing of the pre-beta-amyloid protein by cathepsin D is enhanced by a familial Alzheimer's disease mutation. Eur. J. Biochem. 224:265-271.
Evin, G., Cappai, R., Li, Q. X., Culvenor, J. G., Small, D. H., Beyreuther, K., and Masters, C. L. 1995. Candidate gammasecretases in the generation of the carboxyl terminus of the Alzheimer's disease beta A4 amyloid: possible involvement of cathepsin D. Biochemistry 34:14185-14192.
Mackay, E. A., Ehrhard, A., Moniatte, M., Guenet, C., Tardif, C., Tarnus, C., Sorokine, O., Heintzelmann, B., Nay, C., Remy, J. M., Higaki, J., Van Dorsselaer, A., Wagner, J., Danzin, C., and Mamont, P. 1997. A possible role for cathepsins D, E, and B in the processing of beta-amyloid precursor protein in Alzheimer's disease. Eur. J. Biochem. 244:414-425.
Lippa, C. F., Saunders, A. M., Smith, T. W., Swearer, J. M., Drachman, D. A., Ghetti, B., Nee, L., Pulaski-Salo, D., Dickson, D., Robitaille, Y., Bergeron, C., Crain, B., Benson, M. D., Farlow, M., Hyman, B. T., George-Hyslop, S. P., Roses, A. D., and Pollen, D. A. 1996. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology 46:406-412.
Roth, M. G., Doyle, C., Sambrook, J., and Gething, M. J. 1986. Heterologous transmembrane and cytoplasmic domains direct functional chimeric influenza virus hemagglutinins into the endocytic pathway. J. Cell Biol. 102:1271-1283.
Mathews, P. M., Jiang, Y., C. B., G., Schmidt, S. D., Peterhoff, C. M., Cataldo, A. M., and Nixon, R. A. 2000. Accelerated A-beta generation in AD models of lysosomal system upregulation. [abstract] in World Alzheimer Congress 2000, Washington D.C.
Seglen, P. O., Gordon, P. B., and Holen, I. 1990. Non-selective autophagy. Cell Biol. 1:41-48.
Nixon, R. A. and Cataldo, A. M. 1995. The endosomal-lysosomal system of neurons: new roles. Trends Neurosci. 18:489-496.
Cataldo, A. M., Barnett, J. L., Berman, S. A., Li, J., Quarless, S., Bursztajn, S., Lippa, C., and Nixon, R. A. 1995. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron 14:671-680.
Schwagerl, A. L., Mohan, P. S., Cataldo, A. M., Vonsattel, J. P., Kowall, N. W., and Nixon, R. A. 1995. Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. J. Neurochem. 64:443-446.
Mathews, P. M., Cataldo, A. M., Duff, K. E., Jiang, Y., Peterhoff, C. M., Picciano, M. J., Beard, M. E., and Nixon, R. A. 1999. Lysosomal system activation in presenilin 1-linked familial Alzheimer's disease. [abstract] in Society for Neuroscience, Miami, Florida.
Cataldo, A. M., Hamilton, D. J., and Nixon, R. A. 1994. Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease. Brain Res. 640:68-80.
Callahan, L. M., Vaules, W. A., and Coleman, P. D. 1999. Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 58:275-287.
Green, G. D. and Shaw, E. 1981. Peptidyl diazomethyl ketones are specific inactivators of thiol proteinases. J. Biol. Chem. 256: 1923-1928.
Nixon, R. A. and Cataldo, A. M. 1993. The lysosomal system in neuronal cell death: a review. Ann. NY Acad. Sci. 679:87-109.
Bednarski, E., Ribak, C. E., and Lynch, G. 1997. Suppression of cathepsins B and L causes a proliferation of lysosomes and the formation of meganeurites in hippocampus. J. Neurosci. 17:4006-4021.
Bednarski, E., Lauterborn, J. C., Gall, C. M., and Lynch, G. 1998. Lysosomal dysfunction reduces brain-derived neurotrophic factor expression. Exp. Neurol. 150:128-135.
Ivy, G. O., Kitani, K., and Ihara, Y. 1989. Anomalous accumulation of tau and ubiquitin immunoreactivities in rat brain caused by protease inhibition and by normal aging: a clue to PHF pathogenesis? Brain Res. 498:360-365.
Yang, A. J., Chandswangbhuvana, D., Margol, L., and Glabe, C. G. 1998. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta 1-42 pathogenesis. J. Neurosci. Res. 52:691-698.
Cataldo, A. M., Barnett, J. L., Mann, D. M., and Nixon, R. A. 1996. Colocalization of lysosomal hydrolase and beta-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimer's disease and Down's syndrome. J. Neuropathol. Exp. Neurol. 55:704-715.
Cataldo, A. M., Paskevich, P. A., Kominami, E., and Nixon, R. A. 1991. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease [published erratum appears in Proc Natl Acad Sci USA 1992 Mar 15;89(6):2509]. Proc. Natl. Acad. Sci. USA 88:10998-11002.
Cataldo, A. M., Thayer, C. Y., Bird, E. D., Wheelock, T. R., and Nixon, R. A. 1990. Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: evidence for a neuronal origin. Brain Res. 513:181-192.
Helpern, J., Dyakin, V., Ardekani, B., Duff, K., Wisniewski, T., de Leon, M., Branch, C., O'Shea, J., and Nixon, R. 2000. High-field MRI of neuropathology in the PS-APP transgenic mouse in World Alzheimer Congress 2000, Washington, D.C.
Touitou, I., Capony, F., Brouillet, J. P., and Rochefort, H. 1994. Missense polymorphism (C/T224) in the human cathepsin D pro-fragment determined by polymerase chain reaction-single strand conformational polymorphism analysis and possible consequences in cancer cells. Eur. J. Cancer 3:390-394.
McIlroy, S. P., Dynan, K. B., McGleenon, B. M., Lawson, J. T., and Passmore, A. P. 1999. Cathepsin D gene exon 2 polymorphism and sporadic Alzheimer's disease. Neurosci. Lett. 273:140-1.
Pope, A., Amelotte, J. A., Belfer, H., and Nixon, R. A. 1981. Protease activities in normal and schizophrenic human prefrontal cortex and white matter. Neurochem. Res. 6:1043-1052.
Cohen, G. M. 1997. Caspases: the executioners of apoptosis. Biochem. J. 326, 1-16.
Wang, K. K., Posmantur, R., Nadimpalli, R., Nath, R., Mohan, P., Nixon, R. A., Talanian, R. V., Keegan, M., Herzog, L., and Allen, H. 1998. Caspase-mediated fragmentation of calpain inhibitor protein calpastatin during apoptosis. Arch. Biochem. Biophys. 356:187-196.
Marks, N., Berg, M. J., Guidotti, A., and Saito, M. 1998. Activation of caspase-3 and apoptosis in cerebellar granule cells. J. Neurosci. Res. 52:334-341.
Masliah, E., Mallory, M., Alford, M., Tanaka, S., and Hansen, L. A. 1998. Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. J. Neuropathol. Exp. Neurol. 57:1041-1052.
Skulachev, V. P. 1998. Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett. 423:275-280.
Zamzami, N., Marzo, I., Susin, S. A., Brenner, C., Larochette, N., Marchetti, P., Reed, J., Kofler, R., and Kroemer, G. 1998. The thiol crosslinking agent diamide overcomes the apoptosisinhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition. Oncogene 16:1055-1063.
Kroemer, G. 1997. The proto-oncogene Bcl-2 and its role in regulating apoptosis [published erratum appears in Nat Med 1997 Aug;3(8):934]. Nat. Med. 3:614-20.
Reed, J. C. 1997. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv. Pharmacol. 41:501-532.
Salomons, G. S., Brady, H. J., Verwijs-Janssen, M., Van Den Berg, J. D., Hart, A. A., Van Den Berg, H., Behrendt, H., Hahlen, K., and Smets, L. A. 1997. The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int. J. Cancer 71:959-965.
Xiang, J., Chao, D. T., and Korsmeyer, S. J. 1996. BAX-induced cell death may not require interleukin 1 beta-converting enzymelike proteases. Proc. Natl. Acad. Sci. USA 93:14559-563.
Deiss, L. P., Galinka, H., Berissi, H., Cohen, O., and Kimchi, A. 1996. Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha. EMBO J. 15:3861-70.
Shibata, M., Kanamori, S., Isahara, K., Ohsawa, Y., Konishi, A., Kametaka, S., Watanabe, T., Ebisu, S., Ishido, K., Kominami, E., and Uchiyama, Y. 1998. Participation of cathepsins B and D in apoptosis of PC12 cells following serum deprivation. Biochem. Biophys. Res. Commun. 251:199-203.
Wu, G. S., Saftig, P., Peters, C., and El-Deiry, W. S. 1998. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 16:2177-2183.
Isahara, K., Ohsawa, Y., Kanamori, S., Shibata, M., Waguri, S., Sato, N., Gotow, T., Watanabe, T., Momoi, T., Urase, K., Kominami, E., and Uchiyama, Y. 1999. Regulation of a novel pathway for cell death by lysosomal aspartic and cysteine proteinases. Neuroscience 91:233-249.
McVicker, B. L. and Casey, C. A. 1999. Ethanol-impaired hepatic protein trafficking: concepts from the asialoglycoprotein receptor system. Clin. Biochem. 32:557-61.
Calkins, C. C., Sameni, M., Koblinski, J., Sloane, B. F., and Moin, K. 1998. Differential localization of cysteine protease inhibitors and a target cysteine protease, cathepsin B, by immuno-confocal microscopy. J. Histochem. Cytochem. 46:745-751.
Shibata, T., Shimoyama, I., Ito, T., Abla, D., Iwasa, H., Koseki, K., Yamanouchi, N., Sato, T., and Nakajima, Y. 1998. The synchronization between brain areas under motor inhibition process in humans estimated by event-related EEG coherence. Neurosci. Res. 31:265-271.
Roberg, K. and Ollinger, K. 1998. Oxidative stress causes relocation of the lysosomal enzyme cathepsin D with ensuing apoptosis in neonatal rat cardiomyocytes. Am. J. Pathol. 152: 1151-1156.
Hellquist, H. B., Svensson, I., and Brunk, U. T. 1997. Oxidantinduced apoptosis: a consequence of lethal lysosomal leak? Redox Report 3:65-70.
Fossel, E. T., Zanella, C. L., Fletcher, J. G., and Hui, K. K. 1994. Cell death induced by peroxidized low-density lipoprotein: endopepsis. Cancer Res. 54:1240-1248.
Brunk, U. T., Dalen, H., Roberg, K., and Hellquist, H. B. 1997. Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts. Free Radic. Biol. Med. 23:616-626.
Ollinger, K. 2000. Inhibition of cathepsin D prevents free-radical-induced apoptosis in rat cardiomyocytes. Arch. Biochem. Biophys. 373:346-351.
Roberg, K., Johansson, U., and Ollinger, K. 1999. Lysosomal release of cathepsin D precedes relocation of cytochrome c and loss of mitochondrial transmembrane potential during apoptosis induced by oxidative stress. Free Radic. Biol. Med. 27:1228-1237.
Kessels, M. M., Engqvist-Goldstein, A. E., and Drubin, D. G. 2000. Association of mouse actin-binding protein 1 (mAbpl/SH3P7), an Src kinase target, with dynamic regions of the cortical actin cytoskeleton in response to Rac 1 activation. Mol. Biol. Cell 11:393-412.
Heinrich, M., Wickel, M., Schneider-Brachert, W., Sandberg, C., Gahr, J., Schwandner, R., Weber, T., Saftig, P., Peters, C., Brunner, J., Kronke, M., and Schutze, S. 1999. Cathepsin D targeted by acid sphingomyelinase-derived ceramide [published erratum appears in EMBO J 2000 Jan 17;19(2):315]. EMBO J. 8:5252-5263.
Yamashima, T., Kohda, Y., Tsuchiya, K., Ueno, T., Yamashita, J., Yoshioka, T., and Kominami, E. 1998. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuroprotection based on 'calpain-cathepsin hypothesis'. Eur. J. Neurosci. 10: 1723-1733.
Kinscherf, R., Claus, R., Wagner, M., Gehrke, C., Kamencic, H., Hou, D., Nauen, O., Schmiedt, W., Kovacs, G., Pill, J., Metz, J., and Deigner, H. P. 1998. Apoptosis caused by oxidized LDL is manganese superoxide dismutase and p53 dependent. FASEB J. 12:461-467.
Martin, A., Wu, D., Meydani, S., Blumberg, J., and Meydani, M. 1998. Vitamin E protects human aortic endothelial cells from cytotoxic injury induced by oxidized LDL in vitro. Nutritional Biochem. 9:201-208.
Sawamura, T., Kume, N., Aoyama, T., Moriwaki, H., Hoshikawa, H., Aiba, Y., Tanaka, T., Miwa, S., Katsura, Y., Kita, T., and Masaki, T. 1997. An endothelial receptor for oxidized low-density lipoprotein. Nature 386:73-77.
Li, W., Yuan, X. M., Olsson, A. G., and Brunk, U. T. 1998. Uptake of oxidized LDL by macrophages results in partial lysosomal enzyme inactivation and relocation. Arterioscler. Thromb. Vasc. Biol. 18:177-184.
Dehouck, B., Fenart, L., Dehouck, M. P., Pierce, A., Torpier, G., and Cecchelli, R. 1997. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138:877-889.
Shwaery, G. T., Vita, J. A., and Keaney, J. F., Jr. 1998. Antioxidant protection of LDL by physiologic concentrations of estrogens is specific for 17-beta-estradiol. Atherosclerosis 138:255-262.
Negre-Salvayre, A., Pieraggi, M. T., Mabile, L., and Salvayre, R. 1993. Protective effect of 17 beta-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells. Atherosclerosis 99:207-217.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nixon, R.A., Cataldo, A.M. & Mathews, P.M. The Endosomal-Lysosomal System of Neurons in Alzheimer's Disease Pathogenesis: A Review. Neurochem Res 25, 1161–1172 (2000). https://doi.org/10.1023/A:1007675508413
Issue Date:
DOI: https://doi.org/10.1023/A:1007675508413